ArticleLife (Basel, Switzerland)2026
Risk Factors for Relapse and Surgical Intervention in Children with CTEV Treated by Ponseti Method.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Ponseti method is the gold standard for managing congenital talipes equinovarus (CTEV); however, relapses leading to surgical intervention remain a significant challenge. We investigated the factors associated with a higher risk of relapse. A retrospective study of 31 children (≤4 years) with CTEV treated with the Ponseti method between January 2014 and December 2023 was conducted. Demographic and clinical data-age at treatment, aetiology, Pirani score, number of casts, percutaneous Achilles tenotomy (PAT), surgery, bracing, relapses, and follow-up-were collected. Descriptive statistics, univariate analyses, and logistic regression were conducted to identify risk factors for relapse. Of the 31 patients, 67.7% were male, 58.1% had bilateral involvement and 71.0% had idiopathic CTEV. The median age at presentation was 2 months (IQR 1-3), and the initial Pirani score 5.0, improving to 0.0 at final follow-up (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.